What Intelligent Bio Solutions does

Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company that develops and commercializes non-invasive drug screening products based on fingerprint sweat analysis. Founded in 2017 and headquartered in New York with operating offices in Sydney (Australia) and Cambridge (UK), INBS serves workplace safety programs in construction, transportation/logistics, manufacturing, mining, and forensic/coroner settings, plus justice and rehabilitation programs through its continuous-monitoring product line. The company sells into 35+ countries and territories via direct enterprise sales and a network of more than a dozen regional distributors, reporting 480+ active customer accounts.

The company's core offering is the Intelligent Fingerprinting Drug Screening System, which pairs single-use tamper-proof Drug Screening Cartridges (lateral flow assay with fluorescence-labelled antibodies) with the portable DSR-Plus fluorescence reader. Sample collection takes seconds and results are displayed in under ten minutes at the point of collection, with cartridge revenue at 66% of Q3 FY2026 revenue ($703,538, up 59% YoY). The portfolio also includes the SmarTest Patch, a wearable 7–10-day continuous sweat-monitoring patch targeting justice and rehabilitation use cases, and a confirmatory LC-MS/MS laboratory testing kit executed through NATA-accredited partner Racing Analytical Services Limited. INBS holds eight granted European patents covering the underlying sweat-analysis methodology and reader/cartridge technology.

INBS operates a razor-razorblade model: DSR-Plus reader placements (up 104% YoY in Q2 FY2026 to $246,519) build the installed base that generates recurring cartridge consumable revenue and other consumables/services (21% of Q3 revenue). Pricing is quote-based and not publicly disclosed, though management cites approximately 50% cost reduction vs. urine-based testing as the headline value proposition. Q3 FY2026 revenue was $1.06M (up 46% YoY), nine-month FY2026 revenue was $3.07M (up 39% YoY), and gross margin crossed 50% for the first time. The company is actively pursuing FDA 510(k) clearance — Cut-off Study completed April 2026, Interference and Method Comparison studies initiated June 2026 — which would unlock the multi-billion-dollar U.S. drug screening market and the projected ~$1.62B U.S. roadside testing market by 2030. To support scaling, INBS signed a strategic manufacturing partnership with Syrma Johari MedTech (announced December 2025) projected to deliver over 40% production cost savings and approximately 20 percentage points of gross margin improvement at ~4x prior capacity, with the first reader shipments received in February 2026.

Name

Intelligent Bio Solutions

Legal name

Intelligent Bio Solutions Inc.

Website

https://ibs.inc

Company type

Public

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Drug Screening Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Drug-of-Abuse & Toxicology Rapid Tests (Urine/saliva panels) (HLAHAOAG)

Keywords

• Drug screening systems
• Fingerprint drug testing
• Non-invasive diagnostic devices
• Workplace drug screening
• Point of care testing

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Cartridge Sales (Recurring Consumables): Razor-razorblade model where reader placements generate recurring cartridge revenue. Cartridge sales represent 66% of quarterly revenue ($703,538 in Q3 FY2026), up 59% year-over-year. This is the primary growth driver as installed base expands.
2. Reader Hardware Sales: Initial reader hardware sales (DSR-Plus fluorescence reader) that create the installed base for recurring cartridge revenue. Reader sales surged 104% year-over-year in Q2 FY2026 to $246,519.
3. Other Revenue: Other sales including supplementary products and services, representing 21% of Q3 revenue ($217,857), up 80% year-over-year, indicating broadening product ecosystem.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels8 records

Core offering

Intelligent Bio Solutions develops and sells the Intelligent Fingerprinting Drug Screening System, which uses lateral flow assay cartridges and a portable DSR-Plus fluorescence reader to detect drug metabolites in fingerprint sweat. Sample collection takes seconds and results are produced in under ten minutes at the point of collection. The company also sells the SmarTest Patch, a wearable sweat patch for continuous drug detection over 7–10 days.

Product overview

Intelligent Bio Solutions offers a unified portfolio of non-invasive drug testing products based on fingerprint sweat analysis. The core offering is the Intelligent Fingerprinting Drug Screening System, comprising single-use Drug Screening Cartridges and the portable DSR-Plus Drug Screening Reader, which provides rapid point-of-collection screening for opiates, cocaine, methamphetamine, and cannabis with results in under 10 minutes. This is complemented by the SmarTest Patch, a wearable sweat patch enabling continuous 7-10 day drug monitoring for longer-term detection in justice and rehabilitation settings. The portfolio also includes a Confirmatory Drug Test Kit with LC-MS/MS laboratory analysis through accredited partner RASL for situations requiring definitive confirmation of non-negative screening results. Together, these products provide both immediate and continuous non-invasive sweat-based drug detection solutions.

Differentiator

Problem solved

Functional benefit

Brands

• Intelligent Fingerprinting Drug Testing Solution: Non-invasive fingerprint sweat analysis drug testing system that screens for recent drug use including opiates, cocaine, methamphetamine, and cannabis with results in under ten minutes
• SmarTest Patch

Products and services

• Intelligent Fingerprinting Drug Screening System A rapid, non-invasive drug screening system that detects recent drug use (opiates, cocaine, methamphetamine, cannabis) by analysing fingerprint sweat. Combines single-use Drug Screening Cartridges with the portable DSR-Plus Reader; samples collected in seconds and results returned in under ten minutes. Designed for workplace screening by non-specialist staff.
• Drug Screening Cartridges Single-use, tamper-proof lateral flow assay cartridges that collect fingerprint sweat and use fluorescence-labelled antibodies to selectively detect specific drugs or their metabolites. Self-locking sample seals support chain-of-custody integrity. Sold as recurring consumables for use with the DSR-Plus Reader.
• DSR-Plus Drug Screening Reader A portable, highly sensitive fluorescence measurement instrument used to read Drug Screening Cartridges, producing negative or non-negative results for each drug within minutes. Designed for use by non-laboratory workplace personnel without specialised facilities.
• SmarTest Patch A discreet, wearable sweat drug testing patch worn on the upper arm, chest, or back that enables continuous drug detection over a 7 to 10-day period. Tamper-evident and water-resistant; monitors substances including fentanyl, cocaine, opiates, benzodiazepine, buprenorphine, and methadone. Designed for longer-term monitoring in justice and rehabilitation settings.

Quantifiable outcome

• 50% cost reduction vs urine-based testing
• +5 more outcomes

Named customers7 records

Segments7 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core.

• Bouygues UKcoreChannel Partner/ Reseller/ Distributor · 24 February 2026Initial 13-site deployment with UK subsidiary of Bouygues Construction (global construction firm with 35,600 employees across 50+ countries). Transition from third-party testing services to in-house INBS fingerprint drug testing. Joint ROI analysis validated superior hygiene, operational efficiency, and cost savings. Viewed as collaborative partnership rather than traditional supplier agreement.
• CenExel Clinical Research, Inc.coreImplementation/ SI/ Consulting Partner · 1 January 2026Nationwide clinical research site network partnership for FDA 510(k) clinical studies. Conducting Interference Study enrolling 75 participants, Method Comparison Study with 135 donor and 9 operator participants, and supporting Cut-off Study. Studies conducted under ICH GCP Guidelines to generate clinical evidence required for FDA submission.
• Syrma Johari MedTech Ltd.coreTechnology or Integration · 31 December 2025Strategic manufacturing partnership to produce Intelligent Fingerprinting Drug Screening Reader. Expected to deliver over 40% reduction in annual production costs and approximately 20 percentage point improvement in gross margin. Syrma Johari's manufacturing capacity is approximately four times INBS's current capability with ISO 13485, MDSAP, FDA, and GMP certifications across 14 manufacturing locations in India, Europe, and the US. First readers successfully manufactured and shipped in February 2026.
• Vlepis Pty Ltd.coreStrategic or Co-development Partner · 18 December 2025Non-exclusive strategic alliance to jointly develop and commercialize non-invasive testing and wearable health monitoring technologies. Leverages Vlepis's wearable patch and sensor technologies alongside INBS's fingerprint-based testing and SmarTest Patch products. Targets consumer health monitoring market valued at USD 42.7 billion in 2024, projected to reach USD 168.3 billion by 2030. Companies will combine R&D capabilities, distribution networks across 24+ countries, and regulatory expertise.
• Racing Analytical Services Limited (RASL)coreImplementation/ SI/ Consulting PartnerNATA-accredited laboratory partner performing fingerprint confirmatory drug testing procedure. Provides gold standard LC-MS/MS analysis to confirm screening results and validate system accuracy for FDA 510(k) submission studies.

Scale indicators15 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• OraSure Technologies: OraSure develops rapid point-of-care diagnostics including oral-fluid drug testing products (Intercept). It is the most direct comparable to INBS in non-invasive rapid drug screening.
• Psychemedics Corporation: Psychemedics pioneered hair-based workplace drug testing. It competes in the same employer drug-testing use cases as INBS via a different non-invasive sample matrix.
• Drägerwerk: Dräger's Dräger DrugTest 5000 is a well-established oral-fluid point-of-collection workplace drug testing system, making it a direct head-to-head competitor in safety-critical industries where INBS also sells.
• American Screening Corporation: American Screening distributes rapid drug test kits and point-of-care testing devices for workplace, clinical, and at-home use across multiple methodologies including urine, saliva, and surface tests.

Broad incumbents

• Quest Diagnostics: Quest Diagnostics operates one of the largest clinical laboratory networks in the U.S. and is a major employer drug testing incumbent. INBS positions itself as a faster, point-of-collection alternative to lab-based urine testing.
• Abbott Laboratories (Diagnostics): Abbott's diagnostics franchise spans rapid point-of-care and laboratory drug/toxicology testing. As a broad incumbent, Abbott is a likely competitor or potential partner for any FDA-cleared rapid drug screening platform.
• Thermo Fisher Scientific: Thermo Fisher offers laboratory analytical instruments, reagents, and clinical diagnostics consumables overlapping with both INBS's DSR-Plus reader and lateral flow cartridge chemistry.
• Bio-Rad Laboratories: Bio-Rad manufactures clinical diagnostics and life science research instruments, including quality controls and immunoassay reagents relevant to lateral flow and laboratory drug screening workflows.

Emerging players

• Confirm BioSciences: Confirm BioSciences sells rapid urine- and saliva-based drug testing kits to workplace, clinical, and at-home users — an emerging player in the same customer segments INBS targets via fingerprint sweat.
• Premier Biotech: Premier Biotech manufactures and distributes point-of-care drug screening devices and test cups for workplace and clinical use, overlapping with INBS's workplace drug-testing go-to-market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/ibs_inc_
• YouTubeyoutube.com/@IntelligentBioSolutions
• Facebookfacebook.com/people/Intelligent-Bio-Solutions/61576675250004
• LinkedInlinkedin.com/company/ibsinc
• Instagraminstagram.com/intelligentbiosolutions

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds7 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Intelligent Bio Solutions